Announcement under Regulation 30 (LODR)- Press Release.
HIKAL · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Hikal reported Q4 FY26 revenue of ₹519 crore with EBITDA of ₹105 crore (20.3% margin), up from Q3's 17% EBITDA margin. PAT stood at ₹14 crore. Full year FY26 revenue was ₹1,713 crore with 12.9% EBITDA margin. The company recorded an exceptional charge of ₹47 crore for impairment of manufacturing assets at Panoli. Pharmaceuticals contributed ₹292 crore (56%) and Crop Protection ₹228 crore (44%) in Q4. The Pharma business recovered from H1 regulatory headwinds with improving customer offtake, while Crop Protection showed 45% sequential growth. Management declared a final dividend of 20% of face value. The company highlighted strategic investments in HPAPI and ADC capabilities, expanded Pune kilo lab for CDMO services, and progress on US FDA remediation CAPAs. Personal Care and Specialty Chemicals commercialization is on track for FY27.
Sequential margin improvement to 20.3% in Q4 signals successful execution on operational discipline and better product mix. The impairment charge of ₹47 crore is a one-time hit but the recovery in both Pharma and Crop Protection businesses, combined with a growing CDMO pipeline, positions Hikal for improved FY27 performance.